GlassScriptPhysician profile
Sana Ali
NPI 1043037278
$1,776.48
in general payments reported to CMS, 2019-2025
19 companies · $1,558 in 2025
The $1,558 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $219 · 2025: $1,558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,776.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $291.04 | 2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $272.62 | 2024-2025 | Amvuttra |
| Novo Nordisk INC | $164.29 | 2024-2025 | Ozempic, Wegovy |
| Amgen INC. | $158.04 | 2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.36 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $113.20 | 2025 | Camzyos |
| Pfizer INC. | $93.95 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $89.36 | 2025 | Lifevest |
| Merck Sharp & Dohme LLC | $60.14 | 2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $58.65 | 2025 | |
| Bridgebio Pharma, INC. | $51.82 | 2025 | Attruby |
| Abiomed | $51.52 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $47.61 | 2025 | |
| Azurity Pharmaceuticals, INC. | $38.27 | 2025 | Edarbi |
| Idorsia Pharmaceuticals US INC | $35.68 | 2025 | Tryvio |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.69 | 2025 | Nexletol |
| Boston Scientific Corporation | $27.35 | 2025 | Watchman Access System |
| Cordis US Corp. | $23.19 | 2025 | Mynx Control |
| Lilly USA, LLC | $17.70 | 2025 | Zepbound, Mounjaro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sana Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.